Rapport Therapeutics与天纳西亚生物科技就Rap-219在大中华区的开发与商业化达成战略合作

美股速递
Mar 09

Rapport Therapeutics, Inc. 与天纳西亚生物科技公司今日共同宣布,双方已达成一项战略性合作协议,将携手推进创新药物Rap-219在大中华区(包括中国大陆、香港、澳门及台湾)的开发与商业化进程。此次合作旨在整合双方在研发、临床及市场拓展方面的优势资源,加速该疗法惠及广大患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10